Thai healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) ...

Market participants expect Sybos to make a total exit from Ebos when escrow arrangements expire as it is diversifying away ...

Thai patients gain faster access to next-generation treatments as Zuellig and Lilly deepen their healthcare partnership.

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Zuellig Pharma introduces Eli Lilly’s innovative obesity and diabetes medicine, Mounjaro in Thailand: Bangkok, Thailand Thursday, May 29, 2025, 11:00 Hrs [IST] Zuellig Pharma, a ...

(MENAFN- Dubai PR Network) Mounjaro (tirzepatide) will be available in the market from the end of May 2025 BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading ...

This represents a significant step forward in our commitment to making healthcare more accessible, particularly in the chronic metabolic disease market," said Rehan Saghir, Executive Vice President of ...

Mounjaro. Prescribing Information. Eli Lilly Asia, Inc. Division of Non-communicable Disease, Department of Disease Control, Ministry of Public Health) Yang, T., Qi ...

UBS launched a $NZ950 million ($880 million) block trade in EBOS Group after-market on Wednesday on behalf of major ...

BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounja ...

BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro ® (tirzepatide), the innovative obesity and ...